Lucideon and partners awarded grant

LUCIDEON

Lucideon, the materials technology company, together with nine European consortium partners, has been awarded €3.9m (£2.8m) grant by the European Commission to train industry Ph.D. researchers for the development of drug-free antibacterial materials used for medical applications, such as wound care and implants.

Biomedical polymers have been widely used in combination with drugs in medical settings but a challenge has arisen to develop new materials that have an intrinsic antibacterial functionality. To meet this need, a new generation of professionals will be trained under the project ‘Drug-Free Antibacterial Hybrid Biopolymers for Medical Applications (HyMedPoly)’ which Lucideon is coordinating.

HyMedPoly will engage fifteen young Ph.D. researchers to create and implement new strategies to combat bacteria. Seven of these researchers will be jointly supervised by Lucideon together with two universities, Friedrich-Alexander-UniversitätErlangen-Nürnberg and University of Southampton, the research institute, Fraunhofer Gesellschaft and industry partner Vornia Ltd.

The four-year long project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 643050. It forms part of the European Commission’s initiative to develop European Industrial Doctorates with equal exposure to academics and industry, allowing them to combine research knowledge with business acumen. HyMedPoly will offer a joint training program at world class academic and industrial institutes, combining technical knowledge with hands-on training in state-of-the-art research projects related to key issues that determine the future therapies of antibacterial materials.

Here is what Dr. Xiang Zhang, Royal Society Industry Fellow, Head of Medical Materials and Devices at Lucideon and coordinator of the HyMedPoly project, had to say about it:

“This European Industrial Doctorates program is a new initiative for training future professionals for industry. The unique advantage of the new training scheme is that industry is directly involved in supervising Ph.D. projects together with universities so that young researchers can gain industry knowledge and experiences during their Ph.D. study.

“This is the first time that an industry partner has coordinated a Ph.D. training project to develop new biomaterials in the war against bacteria. Due to resistance of bacteria to drugs, infection has become one of the toughest problems in the medical world as there are hardly any effective antibiotics left in the fight against many pathogens. This project is the initial step in developing new therapies through a new combined technology using new hybrid inorganic and polymeric materials with antibacterial functionalities.

“The ultimate goal will be the development of highly-skilled professionals that will play a pivotal role in the production of advanced medical products for hospitals and personal health care, with the potential to enhance the UK and EU economy as well as contributing to the improvement of quality of life for all.”

Lucideon will work collaboratively with nine other European consortium partners: